Does bilirubin protect against hemochromatosis gene (HFE) related mortality?

American Journal of Medical Genetics

Volumn 129 A, Issue 1, 2004, Pages 39-43

  Alizadeh, Behrooz Z ^a   Njajou, Omer T ^a   Houwing Duistermaat, Jeanine J ^a   De Jong, Gerard ^a   Vergeer, Jeannette M ^a   Hofman, Albert ^a   Pols, Huibert A P ^a   Van Duijn, Cornelia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antioxidant; Bilirubin; Hereditary hemochromatosi; HFE; Iron; Mortality; Penetrance

Indexed keywords

BILIRUBIN; FERRITIN; IRON; TRANSFERRIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; HEMOCHROMATOSIS; HETEROZYGOTE; HFE GENE; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATIVE STRESS; PENETRANCE; PRIORITY JOURNAL;

EID: 3342967615     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.30163     Document Type: Article

References (37)

1. Adams PC, Speechley M, Kertesz AE. 1991. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 101:368-372.
2. Adams PC, Brissot P, Powell LW. 2000. EASL International Consensus Conference on Haemochromatosis. J Hepatol 33:485-504.
3. Aisen P, Enns C, Wessling-Resnick M. 2001. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 33:940-959.
4. Bartels H, Bohmer M. 1971. Automatische Bestimmung von Serum-Bilirubin. Z Klin Chem Klin Biochem 9:133-135.
5. Berglund L, Galbraith RA, Emtestam L, Drummond GS, Angelin B, Kappas A. 1999. Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute-phase reactants in man. Pharmacology 59:51-56.
6. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. 2002. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359:211-218.
7. Distante S, Berg JP, Lande K, Haug E, Bell H. 2000. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 47:575-579.
8. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. 2001. Total serum bilirubin and risk of cardiovascular disease in the Farmingham offspring study. AM J Cardiol 87:1196-1200.
9. Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. 1980. Homozygosity for hemochromatosis: Clinical manifestations. Ann Intern Med 93:519-525.
10. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr., Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. 1996. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399-408.
11. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. 2002. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 122:646-651.
12. Gozales S, Erario MA, Tamaro LM. 2000. Heme oxygenase-1 induction and dependent increase in ferritin, a protective antioxidant stratagem in Hemin-treated rat brain. Dev Neurosci 24:161-168.
13. Hanson EH, Imperatore G, Burke W. 2001. HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 154:193-206.
14. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. 1991. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 7:403-422.
15. Hunt SC, Kronenberg F, Eckfeldt JH, Hopkins PN, Myers RH, Heiss G. 2001. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: The NHLBI family heart study. Atherosclerosis 154:747-754.
16. Lavrovsky Y, Song CS, Chatterjee B, Roy AK. 2000. Age-dependent increase of heme oxygenase-1 gene expression in the liver mediated by NF kappaB. Mech Ageing Dev 14:49-60.
17. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
18. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. 1999. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 116:372-377.
19. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt MD, Rosenberg ME. 1992. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in rat. J Clin Invest 90:267-270.
20. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. 1996. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110:1107-1119.
21. Njajou OT, Hollander M, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB, van Duijn CM. 2002. Mutations in HFE gene and stroke. Stroke 33:2363-2366.
22. Njajou OT, Houwing-Duistermaat JJ, Osborne RH, Vaessen N, Vergeer J, Heeringa J, Pols APP, Hofman A, van Duijn CM. 2003. A population-based study of the effect of the HFE C282Y and H63D mutation on iron metabolism. Eur J Hum Genet 11:225-231.
23. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. 1999. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341:718-724.
24. Phatak PD, Ryan DH, Cappuccio J, Oakes D, Braggins C, Provenza K, Eberly S, Sham RL. 2002. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 29:41-47.
25. Powell LW, Leggett BA, Crawford DHG. 1999. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrel MF, Maddrey WC, editors. Schiff's diseases of the liver. Philadelphia: Lippincott-Raven. pp 1107-1130.
26. Ryan TP, Aust SD. 1992. The role of iron in oxygen-mediated toxicities. Crit Rev Toxicol 22:119-141.
27. Ryter WS, Tyrrell RM. 2000. The heme synthesis and degradation pathways: Role in oxidant sensitivity-Hemeoxygenase has both pro and antioxidant properties. Free Radical Bio Med 28:289-309.
28. Schewertner HA, Jakson WG, Tolan G. 1994. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40:18-23.
29. Siow RC, Sato H, Mann GE. 1999. Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: Anti-atherogenic actions of bilirubin and carbon monoxide? Cardiovasc Res 41:385-394.
30. Stocker R, Glazer AN, Ames BN. 1987a. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 84:5918-5922.
31. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. 1987b. Bilirubin is an antioxidant of possible physiological importance. Science 235:1043-1046.
32. Takahashi M, Dore S, Ferris CD, Tomita T, Sawa A, Wolosker H, Borchelt DR, Iwatsubo T, Kim SH, Thinakaran G, Sisodia SS, Snyder SH. 2002. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 28:461-473.
33. Temme EH, Zhang J, Schouten EG, Kesteloot H. 2001. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12:887-894.
34. Van Aken MO, De Craen AJ, Gussekloo J, Moghaddam PH, Vandenbroukr JP, Heijmans BT, Slagboom PE, Westendorp RG. 2002. No increase in mortality among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: The Leiden 85-plus study. Eur J Clin Invest 32:750-754.
35. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, Kotal P. 2002. Gilbert syndrome and ischemic heart disease: Aprotective effect of elevated bilirubin levels. Atherosclerosis 160:449-456.
36. Worwood M. 2001. What is the role of genetic testing in diagnosis of haemochromatosis? Ann Clin Biochem 38:3-19.
37. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. 1996. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 51:859-862.